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Background
Immunomodulation with pembrolizumab (anti-PD-1)
has been shown to reach significant objective response
(RR) and extend overall survival (OS) both in ipilimu-
mab pre-treated and naive patients with metastatic mel-
anoma. While this immunotherapy gives OS and OR
benefits, it can also result in immune-related adverse
events (irAEs) which are generally of low grade and
easily manageable. We retrospectively evaluated if there
was a correlation between occurrence of irAEs with OR
and disease control rate (DCR).
Methods
Inside the expanded access program, pembrolizumab was
given in patients progressing after ipilimumab at dosage of
2 mg/kg every 3 weeks until PD or unacceptable toxicity.
At our Institution 47 patients (25M, 22F) were treated.
The median age was 49 years (range 28-70). All patients
were stage M1c. The median duration of treatment was of
4.5 months (range 1-8).
Results
At a median follow up of 3 months (range 1 – 8+), 11
(23.4%) pts had OR and 21 (44.7%) pts achieved DCR. In
pts with grade 0/1 irAEs OR was 19.2% while in pts with
grade ≥ 2 irAEs was 28.6%. OR was slightly higher
among pts who experienced irAEs but the difference was
not statistically significant (p = 0.45). Also DCR was
slightly higher but not significant among those patients
who experienced an irAEs (11/21, 52.4%) compared with
those who did not (10/26, 38.5%) (p = 0.34). Among
patients with grade 0/1 irAEs was observed 1 (3.8%)
complete response (CR), 4 (15.4%) partial responses
(PR), 5 (19.3%) stable disease (SD) and 16 (61.5%) pro-
gression of disease (PD), while in the group with irAEs
was observed 1 (4.8%) CR, 5 (23.8%) PR, 5 (23.8%) SD
and 10 (47.6%) PD.
Conclusions
OR and DCR with pembrolizumab are similarly observed
among pts who develop irAEs or not. Thus, pts who do
not experience an irAE have the same probability to
reach clinical benefit with pembrolizumab than those
who experienced irAEs
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